Mineralys Therapeutics Inc

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Mineralys Therapeutics advances pivotal clinical programs for cardio renal disorders

Mineralys Therapeutics is making significant strides in addressing aldosterone driven cardio renal disorders, with proactive advancements in clinical trials and a transparent financial overview. While the company faces challenges in addressing the overlap between CKD and hypertension, there are opportunities to capitalize on the potential success of upcoming trials and the market demand for addressing unmet medical needs in this space.

Mineralys Therapeutics reports positive trial results but faces trial timeline delays

Mineralys Therapeutics showcased positive trial results for lorundrostat in treating uncontrolled hypertension, while facing delays in the Advance-HTN trial. The company's strong financial position and upcoming trials present opportunities for future growth, despite challenges in trial timelines and enrollment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in a fireside chat at the Bank of America Securities Health Care Conference, being held in Las Vegas on May 14-16, 2024.

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024.

Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024

Acrivon Therapeutics Inc

Avantis U.S. Small Cap Value ETF

iShares Core S&P Small Cap ETF

iShares Russell 2000 ETF

iShares Russell 2000 Value ETF

NEXTracker Inc

Skyward Specialty Insurance Group Inc

SPDR S&P 500 ETF Trust

Vanguard Small-Cap ETF

Vanguard Russell 2000 ETF

Despite the case for small caps, it is recommended to sell the Russell 2000 and related ETFs due to negative alpha and seasonal factors.

What To Buy After You Sell The Russell 2000

Mineralys Therapeutics, Inc. (MLYS) Q4 2023 Earnings Call Transcript

– Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 a nd Launch-HTN trial in 2H 2025 –

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2023, before the financial markets open on Thursday, March 21, 2024.

Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024

Mineralys: 2nd Half 2024 Hypertension Data Readout

RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (“CKD”) and other diseases driven by abnormally elevated aldosterone, today announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the “PIPE”) for gross proceeds of approximately $120 million, before deducting estimated fees and expenses.

Mineralys Therapeutics Announces $120 Million Private Placement Financing

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that Chief Executive Officer Jon Congleton will be participating in a fireside chat at the Guggenheim Securities 6th Annual Biotechnology Conference, being held in New York City on February 7-8, 2024.

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know

RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointment of Minji Kim, Ph.D. as Chief Business Officer. Adam Levy will remain in his role as Chief Financial Officer.

Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer

– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.

Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

Mineralys Therapeutics Inc. (NASDAQ:MLYS ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer and Chief Business Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Greg Harrison - Bank of America Jack Padovano - Stifel Seamus Fernandez - Guggenheim Securities Mohit Bansal - Wells Fargo Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys Therapeutics Third Quarter 2023 Conference Call. [Operator Instructions].

Mineralys Therapeutics Inc. (MLYS) Q3 2023 Earnings Call Transcript

– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone –

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that members of the senior management will be participating in the Stifel Healthcare Conference being held in New York on November 14-15, the Jefferies London Healthcare Conference being held in London on November 14-16, and the Evercore ISI 6th Annual HealthCONx Conference being held in Miami on November 28-30.

Mineralys Therapeutics to Participate in Three Upcoming Conferences

– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 –

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension –

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2023, after the financial markets close on Tuesday, November 7, 2023.

Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023

Late-breaking poster presentation at ASN's Kidney Week 2023  - - - Poster presentation at AHA's Scientific Sessions 2023

Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

RADNOR, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced the appointments of Daphne Karydas and Glenn Sblendorio to its Board of Directors (the Board). Ms. Karydas and Mr. Sblendorio bring executive, financial and operational leadership experience in biotechnology and biopharmaceuticals markets. In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, September 28, 2023 at 9:10 a.m. ET.

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile –

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

– Lorundrostat, a highly selective aldosterone synthase inhibitor, demonstrated robust, double-digit reduction in systolic blood pressure (BP), including an enhanced response in individuals with elevated body mass index (BMI) –

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

RADNOR, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease and other diseases driven by abnormally elevated aldosterone, today announced it has been selected to present the full results from the Target-HTN Phase 2 trial of lorundrostat in individuals with uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) in an oral poster presentation at the 2023 American Heart Association (AHA) Hypertension Scientific Sessions, which is being held in Boston from September 7–10.

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 199.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Mineralys Therapeutics Inc Stock (MLYS)